The sale of cardiac glycosides varies significantly by country, with Croatia leading in per capita value. In 2023, year-on-year variations showed growth in Croatia while remaining stagnant in most countries. Ireland and Estonia saw declines, with Greece dropping to nil. Over a five-year period, growth was inconsistent, indicative of market volatility and differing healthcare priorities across regions.
Future trends may see growth driven by aging populations, increased prevalence of heart conditions, and evolving healthcare policies. Watch for emerging markets adopting cardiac treatment, potential advancements in alternative therapies, and regulatory changes impacting drug distribution and sales. Continuous market adaptation is essential.
Top countries in Cardiac Glycosides Sales by Country
| # | 10 Countries | US Dollars PPP Per Capita | Last Year | YoY | 5-years CAGR | |
|---|---|---|---|---|---|---|
| 1 | 1 Croatia | 3 | 2023 | +7.14% | +1.39% | View data |
| 2 | 2 Slovenia | 0.3 | 2023 | 0% | 0% | View data |
| 3 | 3 Germany | 0.3 | 2023 | 0% | 0% | View data |
| 4 | 4 Ireland | 0.2 | 2023 | 0% | -7.79% | View data |
| 5 | 5 Iceland | 0.2 | 2023 | 0% | 0% | View data |
| 6 | 6 Greece | 0.1 | 2023 | -100% | View data | |
| 7 | 7 Luxembourg | 0.1 | 2023 | 0% | 0% | View data |
| 8 | 8 Italy | 0.1 | 2023 | 0% | 0% | View data |
| 9 | 9 Australia | 0.1 | 2023 | 0% | 0% | View data |
| 10 | 10 Costa Rica | 0.1 | 2023 | 0% | 0% | View data |
